{"id":"W4403565766","doi":"10.1093/oncolo/oyae237","title":"Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"review","venue":"The Oncologist","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Oncology; Adverse effect; Population; Cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003491525,0.000408381,0.001852339,0.0001030416,0.0001773634,0.00004176591,0.00009824118,0.0001041298,0.0000295435],"category_scores_gemma":[0.00004727301,0.000191462,0.0001841947,0.0002185246,0.0006671791,0.00003043342,0.0000807447,0.0002481164,0.000006157225],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005834597,"about_ca_system_score_gemma":0.0009901419,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000443078,"about_ca_topic_score_gemma":0.0007206221,"domain_scores_codex":[0.9983653,0.0001322266,0.0005765622,0.0004225459,0.0002059448,0.0002973705],"domain_scores_gemma":[0.9984626,0.0007759652,0.0003024334,0.0002569041,0.00009122192,0.0001109287],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0121901,0.001244486,0.0000987036,0.09019083,0.018323,0.0002826718,0.006140702,0.00004855495,0.0000766038,0.001017417,0.003486779,0.8669001],"study_design_scores_gemma":[0.008515986,0.003372801,0.000187439,0.01410182,0.02030595,0.00008674699,0.0003117737,0.0001007583,0.00005342205,0.0001706424,0.9524722,0.0003204373],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001119114,0.9887111,0.000006364847,0.0005671501,0.00009596452,0.006778181,0.002275455,0.00002528634,0.0004214007],"genre_scores_gemma":[0.001999744,0.9899189,0.0001830789,0.00003066157,0.00008762985,0.001658096,0.0002399174,0.00004563733,0.005836299],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9489855,"threshold_uncertainty_score":0.7807593,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2252177205887461,"score_gpt":0.4877370934272039,"score_spread":0.2625193728384578,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}